Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
Asan Medical Center · Locations not reported · Updated 2026-10-29
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
Peking University Cancer Hospital & Institute · Locations not reported · Updated 2026-06-17
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
Shanghai Zhongshan Hospital · 1 locations · Updated 2026-06-08
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute · 1 locations · Updated 2022-10-25
Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)
Vall d'Hebron Institute of Oncology · 3 locations · Updated 2026-11-12
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East · 1 locations · Updated 2026-11-02
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Fujian Medical University Union Hospital · 1 locations · Updated 2026-10-29
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
VA Office of Research and Development · 7 locations · Updated 2026-10-09
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
American Association for Cancer Research · 4 locations · Updated 2026-10-05
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Gruppo Oncologico del Nord-Ovest · 1 locations · Updated 2026-09-23
Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma
Case Comprehensive Cancer Center · 1 locations · Updated 2026-08-18
A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital · 1 locations · Updated 2026-04-29
Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
Qilu Hospital of Shandong University · 1 locations · Updated 2026-04-17
Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer
Qilu Hospital of Shandong University · 1 locations · Updated 2026-04-17
Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
Fudan University · 1 locations · Updated 2026-04-08
Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma
Fudan University · Locations not reported · Updated 2026-04-02
Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
Erasmus Medical Center · 10 locations · Updated 2025-12-22
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
UNICANCER · 22 locations · Updated 2025-12-02
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
Shanghai Zhongshan Hospital · 1 locations · Updated 2025-12-02
Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital · 1 locations · Updated 2025-09-03
Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma
Centre Leon Berard · 3 locations · Updated 2025-04-18
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 locations · Updated 2024-12-27
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
University of Southampton · 14 locations · Updated 2024-11-12
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
Shanghai Chest Hospital · 1 locations · Updated 2024-07-01
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Shanghai Chest Hospital · 1 locations · Updated 2023-12-20
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2023-11-07
Biomarker Investigation for Early Gastric Cancer Detection
Centre Leon Berard · 1 locations · Updated 2026-11-17
ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma
University of Colorado, Denver · 1 locations · Updated 2026-11-16
Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
University Hospital, Basel, Switzerland · 3 locations · Updated 2026-09-18
Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer
Erasmus Medical Center · 1 locations · Updated 2026-09-14
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2026-09-02
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Masaryk Memorial Cancer Institute · 1 locations · Updated 2026-06-24
FAZA PETMRI Gastro-Oesophageal Study
University Health Network, Toronto · 1 locations · Updated 2026-06-10
Liquid Biopsies in Esophageal Cancer
Universitaire Ziekenhuizen KU Leuven · 4 locations · Updated 2026-06-01
Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA
Assistance Publique - Hôpitaux de Paris · Locations not reported · Updated 2026-05-08
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
Natera, Inc. · Locations not reported · Updated 2026-05-04
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Peking University · 1 locations · Updated 2026-04-21
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine · 1 locations · Updated 2026-03-10
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
Shanghai Zhongshan Hospital · 1 locations · Updated 2026-01-05
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
Peking University Cancer Hospital & Institute · Locations not reported · Updated 2025-09-03
Showing 1–40 of 47. Older studies
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.